First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC ...

Sino Bioking (Tianjin) Biological Pharmaceutical Co., Ltd., a tech firm incubated in Beijing's Zhongguancun, known as the country's Silicon Valley, recently announced a major milestone: its ...

Evry, December 11th 2025 - Eukar s, a Paris-based biotechnology company developing the world’s first multifunctional RNA polymerase to boost biomanufacturing yields in mammalian cells, today announced ...

All G, an Australian company producing milk proteins through precision fermentation, has secured a capital injection ...

According to Research by SNS Insider, the U.S. Peptide Therapeutics Market is Set to Reach USD 35.71 Billion by 2032, Supported by Rising Adoption of Precision Biologics and Advances in Peptide ...

An Australian biotech firm says it has successfully used precision fermentation to reproduce the most vital proteins in human ...

All G's human lactoferrin will be bio-equivalent to the native form with greater than 95% purity. As the company's first recombinant human milk protein, it marks a step toward improving early life ...

Diabetes goes beyond just glucose control, and recent advancements in research are enhancing drug development for the disease ...

(GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: ...

All G is gearing up to launch its first product—recombinant bovine lactoferrin—in Q1 2026, says CEO Jan Pacas.

FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial ROSWELL, ...

Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...